Cisplatin (NSC 119875)

Catalog No.S1166 Synonyms: Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP

For research use only.

Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Cisplatin (NSC 119875) Chemical Structure

CAS No. 15663-27-1

Selleck's Cisplatin (NSC 119875) has been cited by 524 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Other DNA/RNA Synthesis Products

Biological Activity

Description Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.
Features One of the most widely used and most potent chemotherapeutic agents. This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[7]
DNA synthesis [1]
(Tumor cells)
In vitro

Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, which culminates in the activation of apoptosis. [1] Cisplatin (30 μM) treated for 6 h induces an apparent activation of Erk in HeLa cells, which is sustained over the following 14 h period. Cisplatin also shows an effective antineoplastic activity by inducing tumor cells death[2]. Cisplatin displays ability to cause renal proximal tubular cell (RPTC) apoptosis, causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively. [4] Cisplatin (800 μM) causes typical features of necrosis of RPTC after treatment for 4 hr. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Human osteosarcoma cells (HOS, 143B, U2OS and MG‑63) MXLD[YxtKGO7Y3zlJIFv[Wy7c3nz MUWyJO69VQ>? Ml\TOFghcA>? NH3OeGlEcXOybHH0bY4hfHKnYYTt[Y51KG2jcnvl[Ix6KGmwY4LlZZNm\CC2aHWgS|IwVSCyb4D1cIF1cW:wIHnuJIFtdCClZXzsJIxqdmW|Lh?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB3OUC4N{c,OzFyNUmwPFM9N2F-
OVC cells (A2780, TOV-112D, and cis-A2780) NFHZT5hE\WyuIFP5eI91d3irY3n0fUBCe3OjeR?= M{\FXlAvPSxiMTygNk42NCB3LDCxNEwhOjBuIHHu[EA2OCEQvF2= NFO0flg1QCCq M{OzUGNwdWKrbnH0bY9vKG:oIHPpd5Bt[XSrbjDhcoQhVUWNIHnubIljcXSxcjDjc4JqdWW2aX7pZkApOTBibl2pJIVvcGGwY3XzJINmdGxiZHXheIghcW5idHjy[YUhd3[jcnnhckBk[W6lZYKgZ4VtdCCuaX7ld{ApSTJ5OECsJHRQXi1zMULEMEBidmRiY3nzMWEzPzhyKT6= Ml;0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFyNUe2NVEoRjNzMEW3OlEyRC:jPh?=
HCC cell lines HepG2 and Huh7 NYDPZpk1S2WubDD2bYFjcWyrdImgZZN{[Xl? MmL2NE0{OCEQvF2= MlTmOFghcA>? Ml;5R2QyOzNtIFjDR{Bk\WyuczDlfIhq[mm2IILld4l{fGGwY3WgeI8h[2m|cHzheIlvNg>? M{TPRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEW2OVMzLz5|MUC1OlU{OjxxYU6=
Saos-2 cells MlPpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= M{S1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 cells NEHVblNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz NH[wXpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC cells NIrNXW1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NHfsOms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Methods Test Index PMID
Western blot ATF3 ; FEN1 ; PD-L1 / p-MEK / MEK / p-STAT3 / STAT3 ; LC3B-I / LC3B-II / Beclin-1 ; p-AMPK / AMPK / p-mTOR / mTOR 20651982 29541412 29228662 26715839
Immunofluorescence H2A.X / RPA ; γ-H2A.X / 53BP1 ; N-cadherin / E-cadherin / Vimentin ; LC3B 28993682 28105207 26715839
Growth inhibition assay Cell viability 26062553
In vivo

Cisplatin has been demonstrated to be efficient in regression tumor growth in a wide variety of animal tumors models, including head and neck cancer xenografts, cervical squamous carcinoma xenografts, testicular carcinoma xenografts, ovarian cancer xenografts, breast carcinoma xenografts, colonic carcinoma, heterotransplanted hepatoblastoma, and so on. Cisplatin (5 mg/kg) given weekly i.v. at the day 1 and 7 induces a tumor growth inhibition (GI) of 77.5% and 85.1% of the serous xenografts Ov.Ri(C) and OVCAR-3, respectively. [6]

Protocol (from reference)

Cell Research:


  • Cell lines: Leukemia L1210/0 cells
  • Concentrations: 7 μg/mL
  • Incubation Time: 2 hours
  • Method:

    L1210/0 cells are maintained in an exponential suspension culture at 37 ℃ in a humidified atmosphere of 5% CO2 in McCoy's medium 5a (modified), supplemented with 15% calfserum, and Fungizone. L1210/0 cells are incubated in Cisplatin (7 μg/mL) for 2 hr at 37 ℃. To measure growth inhibition, the cells are centrifuged, washed once, resuspended in fresh medium at 30 × 103 to 50 × 103 cells/mL, and incubated for 3 days. Cell numbers are determined on a Coulter Counter. An aliquot of cells is diluted with an equal volume of 0.4% trypan blue. Viability is recorded as the percentage of cells that has excluded trypan blue. Cells incubated with Cisplatin as above are also diluted into 0.1% agar and allowed to grow for 2 weeks when colonies are counted.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 300.05


CAS No. 15663-27-1
Storage 2 years 4°C(in the dark) powder
Smiles [NH2-].[NH2-].Cl[Pt+2]Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
What is the appropriate concentration of DMF for cell culture and animal study?

It depends on the cell type. The final concentration of DMF should be better limited to less than 0.1% if possible, or below 1%. Using saline as a vehicle for cisplatin at up to 3mg/ml is recommended. it's a suspension and can be administrated via oral gavage.

Tags: buy Cisplatin (NSC 119875) | Cisplatin (NSC 119875) ic50 | Cisplatin (NSC 119875) price | Cisplatin (NSC 119875) cost | Cisplatin (NSC 119875) solubility dmso | Cisplatin (NSC 119875) purchase | Cisplatin (NSC 119875) manufacturer | Cisplatin (NSC 119875) research buy | Cisplatin (NSC 119875) order | Cisplatin (NSC 119875) mouse | Cisplatin (NSC 119875) chemical structure | Cisplatin (NSC 119875) mw | Cisplatin (NSC 119875) molecular weight | Cisplatin (NSC 119875) datasheet | Cisplatin (NSC 119875) supplier | Cisplatin (NSC 119875) in vitro | Cisplatin (NSC 119875) cell line | Cisplatin (NSC 119875) concentration | Cisplatin (NSC 119875) nmr